JPMorgan

2026

Dual

Score

Strong

<h3 id="key-takeaways">Key Takeaways</h3><ul><li>Citigroup’s Geoff Meacham established a $1,600 price target on LLY—the highest on the Street—suggesting 45% potential upside.</li><li>Berenberg elevated LLY to Buy with a $1,400 target, pointing to approximately 25% upside opportunity.</li><li>Shares of LLY are trading at $1,138, reflecting a 2% gain in Tuesday’s session.</li><li>The pharmaceutical giant commands 60% of the global weight-loss drug market, generating $14.9 billion in quarterly revenue from obesity and diabetes medications.</li><li>Wall Street consensus stands at Strong Buy across 20 analysts, with a mean price target of $1,375.78.</li></ul>Shares of Eli Lilly are capturing Wall Street’s attention as the pharmaceutical giant receives back-to-back endorsements from prominent research firms.<a href="https://knockoutstocks.com/stock/LLY" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/LLY/embed" alt="LLY Stock Card"> Eli Lilly and Company, LLY </a>Citigroup’s Geoff Meacham has established a $1,600 price objective for LLY, marking the most optimistic target on the Street. This forecast suggests roughly 45% appreciation potential from the stock’s present value of $1,138.Meacham, who holds a five-star analyst rating and maintains a 59% accuracy record, reaffirmed his Buy recommendation while highlighting Eli Lilly’s commanding position in the weight-loss pharmaceutical sector.The Indianapolis-based drugmaker controls 60% of the worldwide weight-loss medication market. Its flagship products Zepbound and Mounjaro, targeting obesity and diabetes respectively, are producing $14.9 billion in combined quarterly revenue.The Citigroup analyst also observed that LLY shares have retreated 8% during the past month, creating what he characterizes as an attractive entry point for long-term investors.<h3 id="berenberg-turns-bullish-on-lly">Berenberg Turns Bullish on LLY</h3><a href="https://www.investing.com/news/analyst-ratings/berenberg-upgrades-eli-lilly-stock-rating-on-obesity-drug-strength-93CH-4900820" rel="noopener noreferrer nofollow">Berenberg</a> elevated its stance on LLY from Hold to Buy on Tuesday, simultaneously increasing its price objective to $1,400 from $1,220. The European investment bank projects approximately 25% appreciation from present trading levels.According to Berenberg’s 2026 return on research investment framework, Eli Lilly has consistently demonstrated superior returns compared to industry peers. The firm anticipates the company will exceed its fiscal 2026 projections.The research house identified an approaching catalyst: anticipated diabetes clearance for Foundayo, Eli Lilly’s oral GLP-1 medication. Foundayo generated approximately $100 million in Q2 2026 revenue, with acceleration expected following comprehensive regulatory approval.Berenberg further emphasized Eli Lilly’s robust pipeline development, noting numerous experimental compounds with multibillion-dollar commercial possibilities. The pharmaceutical company has allocated roughly $60 billion across over 25 strategic transactions during the current fiscal year.<h3 id="broad-analyst-support-builds">Broad Analyst Support Builds</h3>Among 20 Wall Street analysts covering LLY, the consensus rating is Strong Buy. The distribution includes 18 Buy recommendations and two Hold ratings. The collective price target averages $1,375.78, indicating roughly 12% upside potential from current trading levels.BMO Capital and JPMorgan have recently reaffirmed their constructive views on LLY. Both institutions maintain $1,400 price objectives, emphasizing expansion in the incretin therapeutic category.<a href="https://knockoutstocks.com/stock/LLY" rel="noopener noreferrer nofollow">Eli Lilly’s</a> fundamental metrics support the optimistic analyst sentiment. The corporation reported approximately 50% revenue expansion over the trailing twelve months and boasts a pristine Piotroski Score of 9.The Medicare Bridge initiative is additionally fueling heightened demand for Eli Lilly’s obesity medications, according to Berenberg’s analysis.Competitor Novo Nordisk, which captures 38% of the global obesity drug market, recently unveiled a corporate rebrand, adopting the simplified identity “Novo.” The Danish pharmaceutical firm will present its comprehensive business roadmap at a Capital Markets Day event scheduled for September 21.Eli Lilly has also announced plans to acquire Merida Biosciences for approximately $2.875 billion in cash, a strategic move designed to bolster its autoimmune and allergic disease treatment portfolio.LLY closed Tuesday’s session at $1,138.28, gaining $22.58, or 2.02%, on the day.The post <a href="https://blockonomi.com/eli-lilly-lly-stock-surges-on-dual-analyst-upgrades-and-1600-price-target/" rel="noopener noreferrer nofollow">Eli Lilly (LLY) Stock Surges on Dual Analyst Upgrades and $1,600 Price Target</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

Eli Lilly (LLY) Stock Surges on Dual Analyst Upgrades and $1,600 Price Target

Table of Contents

Blockonomi

Other articles published on Sep 15, 2026

How Reverse Swap Simulation Changes STON.fi Trade Planning

Solana (SOL) Eyes Breakout Near $102 as Network Triples Transaction Capacity

U.S. Justice Department Seeks to Seize $61M in Cryptocurrency Tied to Iranian Oil Smuggling Ring

Chainlink News: Nazarov Joins BlackRock, Vanguard at Fed Panel

Solana just tripled its transaction capacity, What comes next?

Bitcoin (BTC) Surges Past $79K Amid Iran Peace Signals and Crypto Bill Progress

Join our free newsletter for daily crypto updates!